A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

被引:95
作者
Voena, C
Ladetto, M
Astolfi, M
Provan, D
Gribben, JG
Boccadoro, M
Pileri, A
Corradini, P
机构
[1] UNIV TURIN,DIPARTIMENTO MED & ONCOL SPERIMENTALE,DIV EMATOL,AZIENDA OSPED SAN GIOVANNI BATTISTA,TURIN,ITALY
[2] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115
关键词
B cell malignancies; IgH nested-PCR; minimal residual disease;
D O I
10.1038/sj.leu.2400801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several methods have been developed for the detection of minimal residual disease (MRD) in B cell tumors. Chromosomal translocations or the rearrangement of the immunoglobulin heavy chain (IgH) and T cell receptor genes are generally employed. We report a novel PCR method to detect MRD using IgH genes. IgH rearranged variable region (VDJ) were amplified from tumor specimens using consensus primers for variable and joining region genes. Complementarity-determining regions (CDR) were identified and used to generate tumor-specific primers. Two-round amplifications using primers derived from CDRs and joining or constant regions were performed for MRD detection. IgH nested-PCR approach was tested on a panel of 75 B cell tumors including acute lymphoblastic and chronic lymphocytic leukemias, non-Hodgkin's lymphomas and multiple myelomas. A VDJ sequence was obtained in 62 out of 75 cases (83%). Sensitivity using DNA or cDNA templates was 10(-5) and (-6), respectively. This method is specific and sensitive and provides a simple, non-radioactive approach for the evaluation of MRD in B cell tumors.
引用
收藏
页码:1793 / 1798
页数:6
相关论文
共 31 条
[1]   DEVELOPMENT OF THE PRIMARY ANTIBODY REPERTOIRE [J].
ALT, FW ;
BLACKWELL, TK ;
YANCOPOULOS, GD .
SCIENCE, 1987, 238 (4830) :1079-1087
[2]  
BAHLER DW, 1991, BLOOD, V78, P1561
[3]  
BAKKUS MHC, 1992, BLOOD, V80, P2326
[4]   DETECTION OF MINIMAL RESIDUAL LEUKEMIA BY THE POLYMERASE CHAIN-REACTION - POTENTIAL IMPLICATIONS FOR THERAPY [J].
BARTRAM, CR .
CLINICA CHIMICA ACTA, 1993, 217 (01) :75-83
[5]   OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION [J].
BRISCO, MJ ;
CONDON, J ;
HUGHES, E ;
NEOH, SH ;
SYKES, PJ ;
SESHADRI, R ;
TOOGOOD, I ;
WATERS, K ;
TAURO, G ;
EKERT, H ;
MORLEY, AA .
LANCET, 1994, 343 (8891) :196-200
[6]   DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].
CAMPANA, D ;
PUI, CH .
BLOOD, 1995, 85 (06) :1416-1434
[7]   Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia [J].
Cimino, G ;
Elia, L ;
Rivolta, A ;
Rapanotti, MC ;
Rossi, V ;
Alimena, G ;
Annino, L ;
Canaani, E ;
LoCoco, F ;
Biondi, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (03) :659-664
[8]   HIGH-DOSE SEQUENTIAL CHEMORADIOTHERAPY IN MULTIPLE-MYELOMA - RESIDUAL TUMOR-CELLS ARE DETECTABLE IN BONE-MARROW AND PERIPHERAL-BLOOD CELL HARVESTS AND AFTER AUTOGRAFTING [J].
CORRADINI, P ;
VOENA, C ;
ASTOLFI, M ;
LADETTO, M ;
TARELLA, C ;
BOCCADORO, M ;
PILERI, A .
BLOOD, 1995, 85 (06) :1596-1602
[9]  
CORRADINI P, 1993, BLOOD, V81, P2708
[10]  
CROSS NCP, 1993, BLOOD, V82, P1929